SCHEDULE 13D/A 0001214659-24-016381 0001232621 XXXXXXXX LIVE 2 Common Shares, no par value 02/27/2026 false 0001600620 05156V102 Aurinia Pharmaceuticals Inc.

#140, 14315 - 118 Avenue Edmonton A0 T5L 4S6

Kevin Tang 858-200-3830 4747 Executive Drive Suite 210 San Diego CA 92121 0001232621 N TANG CAPITAL MANAGEMENT, LLC WC N DE 0.00 12229500.00 0.00 12229500.00 12229500.00 N 9.2 OO Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI") and Kevin Tang. The percentages used herein are based on 132,970,979 Common Shares outstanding as of February 25, 2026, as set forth in the Issuer's Annual Report filed on Form 10-K that was filed with the Securities and Exchange Commission on February 26, 2026. 0001178579 N KEVIN TANG WC N X1 0.00 12229500.00 0.00 12229500.00 12229500.00 N 9.2 IN Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, and TCM. 0001191935 N TANG CAPITAL PARTNERS, LP WC N DE 0.00 6990461.00 0.00 6990461.00 6990461.00 N 5.3 PN TCP shares voting and dispositive power over such shares with TCM and Kevin Tang. Y TANG CAPITAL PARTNERS INTERNATIONAL, LP WC N DE 0.00 5239039.00 0.00 5239039.00 5239039.00 N 3.9 PN TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang. Y TANG CAPITAL PARTNERS III, INC WC N NV 0.00 0.00 0.00 0.00 0.00 N 0 CO Y TANG CAPITAL PARTNERS IV, INC WC N NV 0.00 0.00 0.00 0.00 0.00 N 0 CO Common Shares, no par value Aurinia Pharmaceuticals Inc. #140, 14315 - 118 Avenue Edmonton A0 T5L 4S6 This Schedule 13D/A (this "Statement") amends the Schedule 13D (the "Original Schedule 13D") filed on September 12, 2024, as amended on March 4, 2025. Items 3, 5 and 7 of the Statement are hereby amended and supplemented to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D. Item 3 of the Original Schedule 13D is hereby amended to add the following: Since March 4, 2025 the Reporting persons have expended an aggregate of approximately $26.3 million to purchase 2,200,000 of the Issuer's Common Shares through the open market. The Common Shares were acquired in the ordinary course of business. The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 12,229,500 of the Issuer's Common Shares, representing 9.2% of the outstanding shares. See item 5(a) above. Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Common Shares that were effected during the past 60 days by the Reporting Persons. No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Shares beneficially owned by the Reporting Persons. Not applicable Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on March 4, 2025 by the Reporting Persons with respect to the Common Shares of the Issuer). Exhibit 2: Schedule A: Transactions during the past 60 days (as amended). TANG CAPITAL MANAGEMENT, LLC /s/ Kevin Tang 03/03/2026 KEVIN TANG /s/ Kevin Tang 03/03/2026 TANG CAPITAL PARTNERS, LP /s/ Kevin Tang 03/03/2026 TANG CAPITAL PARTNERS INTERNATIONAL, LP /s/ Kevin Tang 03/03/2026 TANG CAPITAL PARTNERS III, INC /s/ Kevin Tang 03/03/2026 TANG CAPITAL PARTNERS IV, INC /s/ Kevin Tang 03/03/2026